enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Genzyme - Wikipedia

    en.wikipedia.org/wiki/Genzyme

    Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...

  3. Sanofi - Wikipedia

    en.wikipedia.org/wiki/Sanofi

    Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...

  4. Vericel - Wikipedia

    en.wikipedia.org/wiki/Vericel

    In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. [1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. [1]

  5. Sanofi-Aventis, Genzyme Are on the Brink of a Merger - AOL

    www.aol.com/news/2011-02-07-sanofi-aventis...

    It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. Sanofi is expected to ...

  6. Sanofi-Aventis Launches Hostile Bid for Genzyme - AOL

    www.aol.com/news/2010-10-04-sanofi-aventis...

    After months of courting U.S. drugmaker Genzyme (GENZ), French pharmaceutical company Sanofi-Aventis (SNY) launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all ...

  7. Sanofi Is in No Rush to Reach Deal With Genzyme - AOL

    www.aol.com/2010/09/15/sanofi-genzyme-offer-deal...

    Sanofi-Aventis (SNY) CEO Chris Viehbacher (pictured) said in a webcast Wednesday he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme (GENZ) at a ...

  8. Recursion Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Recursion_Pharmaceuticals

    By 2015, Recursion had closed its Series A round of funding and signed a research agreement with Sanofi Genzyme. [14] In 2020, the company received $50 million equity investment from Bayer during its Series D funding round. [15] [16] The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX.

  9. Sanofi to Buy Genzyme in $20.1 Billion Deal - AOL

    www.aol.com/news/2011-02-16-sanofi-to-buy...

    French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right ...